Loading
A phase 3 trial of Rilvegostomig and Pembrolizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06868277 by AstraZeneca, with 830 participants planned, started 2025-04-10 and due to reach its primary completion in 2030-01-17. Interventions recorded: Rilvegostomig and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, T-cell exhaustion and CAR-T persistence, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Pembrolizumab and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Pembrolizumab and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/